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ABSTRACT
Objective: The main objective of the present research work was to develop, optimize, and characterize microemulsion (ME) of frovatriptan succinate 
to improve brain transport.
Methods: The pseudoternary phase diagrams were constructed for ME formulations composed of Capmul MCM, Cremophor EL, and propylene glycol. 
Frovatriptan succinate-loaded ME was optimized by simplex lattice design having the concentration of oil, surfactant, and cosurfactant representing 
three apex points on the triangle. These were taken as independent variables and percentage drug release as a response variable. All developed 
batches of ME were characterized for in vitro tests, histopathology study, and pharmacokinetics in Swiss albino rats.
Results: Clear MEs were obtained. F5 having particle size 142.0 nm, zeta potential –17.7 to –7.8 mv, refractive index 1.37±0.21, drug content 
98.25±1.10 %, and drug diffused through dialysis membrane 85 % was was the optimized batch. Drug permeation through the nasal mucosa of F5 in 
the ex vivo study was found to be 82.32%. Histopathology microscopic study has shown that F5 does not cause any irritation and structural changes 
in sheep nasal mucosa. The pharmacokinetic parameters were determined after nasal and oral administration of F5. For brain tissue, after nasal 
administration were Cmax181±1.51 ng/ml, Tmax  2±1.01, area under curve (AUC)0−6  390.0±2.08 ng.h/ml. The AUC0−6 attained by nasal ME was 3.29 times 
greater than oral solution. Drug targeting index of frovatriptan succinate was 2.06. This was found satisfactory.
Conclusion: Microemulsion of said composition was found to be enhancing delivery of frovatriptan succinate to brain tissues through nasal route.
Keywords: Drug targeting index, Frovatriptan, Liquid chromatography–mass spectrometry, Microemulsion, Nasal.
INTRODUCTION
The nasal mucosa has been considered as a route of administration 
to speed up a higher level of drug absorption. Among the mucosal 
sites in the human body, nasal mucosa has the potential to compete 
with the intravenous route for fast onset of action and percentage 
bioavailability [1]. This potential lies in the ability of nasal mucosa of 
high drug permeation due to exceedingly vascularization. In addition, 
the olfactory region of the nose has the potential to stream a drug to the 
central nervous system (CNS) [2]. Therefore, this offers the possibility 
to target CNS by bypassing blood–brain barrier (BBB) [3]. The drugs 
absorbed nasally through olfactory epithelium enter in olfactory 
neurons and supporting cells and subsequently into the brain, which 
reduced the systemic toxicity of centrally acting drugs and enhanced 
therapeutic efficacy [4]. Rapid onset of action is attributed by high 
permeability of nasal mucosa with large surface area [5]. In addition to 
this, nasal administration minimizes the lag time associated with oral 
drug delivery and offers non-invasiveness [6].
Microemulsion is a transparent looking product having a droplet 
size of 20–200 nm composing of oil, surfactant, cosurfactant, and 
water at suitable proportions. It has several specific physicochemical 
properties such as transparency, optical isotropy, low viscosity, and 
thermodynamic stability [7]. These properties made it possible to 
use in a drug delivery system. Hydrophilic and lipophilic drugs can be 
administered through microemulsion (ME) due to its oil and aqueous 
composition. Drug dissolved in components of the ME can cross the 
BBB due to its lipophilicity. Hence, ultimately, it is promising for nasal 
delivery of drugs. There are pieces of evidence of ME used as intranasal 
drug delivery systems targeting to the brain.
Migraine is a neurological disorder with intense, unilateral, throbbing, 
and pulsatile headache attacks that may last for 4–72 h and may be 
accompanied by anorexia, nausea, vomiting, photophobia, and/or 
phonophobia [8]. In connection with migraine, drugs used in treatment 
must be absorbed immediately for fast onset of action and high 
bioavailability. This need can be successfully fulfilled by administration 
of drug-loaded ME through nasal route.
Frovatriptan succinate has a uniquely long-half life than that of 
other triptans. This provides the opportunity to use frovatriptan in 
menstrual-related migraine and other situations, as well as use in 
long-lasting or recurrent migraine. In the pathogenesis of migraine, 
neurogenic inflammation and cerebral vasodilatation are significant 
factors. Activation of 5-HT1D prevents neurogenic inflammation, and 
activation of 5-HT1B reverses cerebral vasodilatation. Frovatriptan has a 
high affinity for 5-HT1D and 5-HT1B receptors. Nonetheless, frovatriptan 
has a moderate affinity for 5-HT1A and 5-HT1F receptors subtypes, and 
it is most potent 5-HT1B agonists [9]. Incomplete absorption from 
the gastrointestinal tract is attributing to the low oral bioavailability 
of frovatriptan that is 22%–30% [10]. Although a single dose 2.5 
mg is recommended, additional doses up to 7.5 mg in a day may be 
administered with intervals of more than 2 h on the basis of recurrence 
of headache. Animal studies have proven that frovatriptan has limited 
capacity to cross the BBB [11].
As intranasal administration offers a practical, non-invasive route of 
administration for drug delivery to the brain [12,13] and intranasal 
microemulsions are promising carriers for achieving the goals in drug 
targeting to brain [14,15]; the objective of this study was to formulate 
and optimize microemulsion of frovatriptan succinate for intranasal 
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delivery. In this work, frovatriptan succinate loaded microemulsions 
were designed by using a simplex lattice experimental design and 
characterized. Microemulsion formulation was optimized and further 
evaluated for drug targeting index (DTI).
MATERIALS AND METHODS
Materials
Frovatriptan succinate was obtained as a gift sample from Glenmark 
Generic Ltd., Navi Mumbai, India. Capmul MCM was obtained as a gift 
sample from Abitec Corporation. Cremophor EL and Cremophor RH 
40 were obtained as a gift sample from BASF India. Labrafil M 2125 
CS, Maisine 35–1, and Plurol Oleique were procured from Gattefosse 
India Pvt. Ltd., Mumbai, India. Tween 80, propylene glycol, and PEG 
400 were purchased from Molychem, India. Hariol 538 medium-
chain triglycerides (MCT oil) and Labrasol were gifted from Subhash 
Chemical Industries Pvt. Ltd., Pune, India. All other ingredients used 
were of analytical grade.
Methods
Estimation of drug content in oils, surfactant, and cosurfactant: Oils, 
surfactants, and cosurfactant were tested for solubility of frovatriptan. 
A suitable solvent system was developed to estimate drug solubility 
in selected ME components. Combination of phosphate buffer pH 6.4 
and methanol found appropriate one. Ratios such as 1:9, 2:8, 3:7, 4:6, 
5:5, 6:4, 7:3, 8:2, and 9:1 v/v were prepared and used as solvent for 
extraction and estimation of drug from ME components. The selected 
ratio was optimized on the basis of solubility of ME component in it. 
Further, the same solvent combination was used to develop calibration 
curve. Different dilutions of concentrations 2–10 µg/ml were prepared 
and absorbances (n=3) of all dilutions were noted at fixed λmax 244 nm 
using Ultraviolet (UV) Spectrophotometer (Shimadzu-1800).
Solubility studies
Capmul MCM, oleic acid, isopropyl myristate, Maisine 35–1, and 
Hariol 538 MCT were selected as oil component for solubility testing. 
Cremophor EL, cremophor RH-40, tween 80, Labrafil M 2125 CS, and 
Labrasol were surfactants and propylene glycol, plurol oleique, PEG 400, 
and ethanol were tested as surfactant and cosurfactant, respectively. To 
define supersaturation solubility, an excess amount of drug was added 
in each vial holding 2 ml of above emulsion components separately [16]. 
Each vial was ultrasonicated to dissolve the excess amount of drug up 
to supersaturation. The vials were kept in orbital shaker for 48 h with 
stirring. Samples were centrifuged at 7500 rpm for 15 min to obtain 
a sufficient amount of supernatant. The drug in this supernatant was 
analyzed by making proper dilution with an optimized ratio of solvent 
by UV spectrophotometer at 244 nm to estimate the solubility of drug.
Construction of phase diagram and preparation of ME formulation
To construct pseudoternary phase diagrams, surfactant:cosurfactant 
ratio was termed as Smix and considered it for one apex of a triangle. 
Rest of the two apexes were of oil and water. A water titration method 
was found suitable to develop different phase diagrams [17]. Smix was 
Cremophor EL: Propylene glycol; 2:1, 3:1, and 4:1 w/w. Selected Smix 
was blended with oil in weight ratios of 1:9, 2:8, 3:7, 4:6, 5:5, 6:4, 7:3, 
8:2, and 9:1. Water was added drop by drop to each mixture under 
proper magnetic stirring at 37°C until the mixture became clear at a 
certain point. After equilibrium, the samples were visually checked and 
determined as being clear MEs [18]. Chemix software (free version) 
was right and proper to create pseudoternary phase diagrams. After 
the identification of ME region in the phase diagrams, the contents of 
oil, Smix, and water at appropriate weight ratios were selected. The MEs 
were selected at desired component ratios. The preparation of selected 
ME was simply performed by adding the weighed components together 
and stirring to form the clear ME.
Preparation of drug-loaded ME
According to the ME formation area in the phase diagrams, the 
frovatriptan succinate-loaded ME formulations were selected at 
different component ratios. Frovatriptan succinate was added 
to the mixtures of oil, surfactant, and cosurfactant under gentle 
ultrasonication with varying component ratios. Then, an appropriate 
amount of distilled water was added to the mixture drop by drop and 
the ME containing frovatriptan succinate was obtained by stirring the 
mixtures at room temperature at constant rpm.
Formulation and optimization of frovatriptan succinate-loaded ME
The simplex lattice design for a three-component system consists of 
an equilateral triangle in two-dimensional space [19]. Seven batches 
(F1-F7) were prepared by taking three independent variables; one at 
each vertex (X1, X2, and X3), one at the halfway point between vertices 
(X1X2, X2X3, and X1X3), and one at the center point (X1X2X3).
The concentration of oil, surfactant, and cosurfactant was selected as 
independent variables. The percentage of drug release after 7 h was 
taken as response.
A simplex lattice design was used using Design–Expert software (trial 
version). In this design, three factors were evaluated by changing their 
concentrations simultaneously and keeping their total concentration 
constant.
Characterization of ME formulation
Frovatriptan succinate-loaded MEs were characterized for appearance, 
pH, viscosity, refractive index, in vitro drug diffusion study, particle 
size/globule size, zeta potential, and drug content.
Identification: Type of ME
It is tested for the type of MEs whether it is o/w or w/o type. A drop was 
put on a filter paper and observed for its spreading and absorption on 
filter paper [20].
pH of ME
The pH measurement for all MEs was carried out using digital pH meter.
Viscosity
Rheological behavior of MEs was noted at room temperature using 
small volume adapter of Brookfield Viscometer (Brookfield, RV DV 
II + Pro).
Refractive index
The refractive index of all MEs was determined using Abbe’s 
refractometer.
In vitro drug diffusion study
In vitro drug diffusion study of all formulations (F1–F7) was carried 
out using Franz diffusion cell [21] having the capacity of 17 ml 
and dialysis membrane (HiMedia; molecular weight cutoff range 
12000–14000 kDa) as diffusion membrane. Pre-diffusion soaking of 
dialysis membrane was carried out in phosphate buffer pH 6.4 for 24 
h. Diffusion cell was filled with phosphate buffer pH 6.4 and dialysis 
membrane was mounted on it. The temperature was maintained at 
34±1°C by circulating water bath. The content of the receptor fluid was 
stirred continuously using a magnetic stirrer. Samples were withdrawn 
at different time intervals and replaced with the same volume of fresh 
sample. Samples were filtered and the amount of drug was estimated by 
UV-visible spectrophotometer at 244 nm.
Particle size and zeta potential
Particle size of all formulations was measured using Zetasizer 
(Nanozydus 90 Malvern Ltd., U.K.). All samples were diluted in a 1:10 
by volume with deionized water to get optimum 100–200 Kilo counts/s 
(KCPS) for measurements.
Drug content
A sample of 0.1 ml of ME was added in selected solvent ratio: Phosphate 
buffers pH 6.4:methanol (1:9 v/v). Methanol of high-performance liquid 
chromatography grade used was filtered, and then, the volume was 
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made up to 10 ml. A 1 ml of this solution was successfully diluted 100 
folds. The resultant solution was analyzed by UV spectrophotometer at 
244 nm. Drug-free ME (blank ME) was also diluted in a similar manner 
and detected at 244 nm [22]. Frovatriptan content was extrapolated 
from the standard curve.
Ex vivo permeation study
Ex vivo permeation study was carried out on sheep nasal mucosa. A fresh 
nasal mucosa was collected from a local slaughter house. Mucosa of the 
olfactory region was targeted to separate skillfully. After separating 
mucosa carefully from nasal tissues, it was kept in phosphate buffer 
pH 6.4 for 1 h to obtain good permeation of drug after saturation with 
phosphate buffer [23]. Thickness of nasal mucosa was 0.85–0.95 mm; 
exposed area of mucosa on diffusion cell membrane was approximately 
2.98 cm2. Ex vivo diffusion drug release was carried out using 6 station 
diffusion cell apparatus (Make: Orchid). At different time intervals, 
sample was withdrawn, then filtered through Whatman filter paper 
(0.45 µm), and analyzed using UV spectrophotometer. Experimental 
conditions such as temperature, the volume of replacement were the 
same like in vitro drug release study.
Histopathological studies
Fresh nasal mucosa used in ex vivo permeation study was carefully 
removed from diffusion cell and stored in 10% of formalin solution 
to avoid bacterial growth. Further, mucosa was cut and stained with 
eosin. One portion of mucosa was treated with phosphate buffer pH 
6.4 and other with isopropyl alcohol (IPA). These samples were used 
as a negative and positive control, respectively. All three sections were 
examined under 40× by light microscope (Motic DMW, B1–223ASC, 
Motic Incorporation Pvt. Ltd.) for microscopic appearance and 
structural alterations if any.
Mucoadhesive strength of the optimized formulation was carried out 
using a modification of the mucoadhesive strength measuring device 
used by Choi et al. [24]. A fresh sheep nasal mucosa was put between 
the two glass vials with ME applied at one side, and the force required 
to detach the vials was measured.
Animal study
The protocol of the animal study was approved by the Institutional 
Animal Ethical Committee of Modern College of Pharmacy, Nigdi, Pune, 
having reference No: MCP/IAEC/35/2011 as per CPCSEA guidelines. 
Swiss albino rats weighing 200–250 g were used for the study. These 
were obtained from the National Toxicological Centre, Pune, India.
Analytical procedure
Liquid chromatography–mass spectrometry (LC/MS) technique 
was developed for analysis of drug using C-18, 150×4.6 mm, 5 µm 
(Chromatopack). For plasma and brain tissue samples, the mobile phase 
consists of 0.1% formic acid in methanol (organic):ammonium acetate 
buffer 10 Mm (aqueous) (85:15) v/v was used. The flow rate was 
1.0 ml/min at ambient temperature. Detection was performed using an 
API-4000 QTRAP instrument (Applied Biosciences AB Sciex) [25].
Sample preparation
The microemulsion was weighed accurately equivalent to 5.0 mg 
of frovatriptan succinate and dissolved in methanol:water. Volume 
adjusted up to the mark 5.0 ml. Thus, 5 mg/5 ml main stock (1000 
ppm) was prepared. Further, dilutions were made in the range of 10, 
20, 50, 200, 400, 600, and 800 ng/ml. Metoclopramide hydrochloride 
1 ng/ml was used as an internal standard. Retention time was 2.08 
min for frovatriptan succinate and 2.18 min for internal standard 
metoclopramide hydrochloride.
Animal experiment and drug administration
A 12 h before and during the pharmacokinetic study, Swiss albino rats 
were fasted. However, they were allowed free access to water. The 
animals were divided into two: Groups A and B in such a way that, to 
one group, nasal ME formulation was administered (Group A) and, 
to another group, oral aqueous formulation of frovatriptan succinate 
(Group B) was administered. Each group consists of six rats. The blood 
samples and brain tissue were collected from each group to analyze 
the quantity of drug after administration by both routes. For Group A, 
optimized ME formulation was administered nasally, and for Group B, 
aqueous solution was administered.
Sample collection and analysis
After administration, blood samples from each group were withdrawn 
from the retro-orbital vein at time intervals of 0.16 (10 min), 2, 4, 5, and 
6 h and were collected in EDTA tubes to prevent clotting of blood. Blood 
samples were centrifuged at 5000 rpm for 10 min to separate plasma. 
Animals were sacrificed for collection of brain tissue at time intervals of 
0.16 (10 min), 2, 4, and 6 h from each group. Brain tissue was separated 
carefully and then rinsed with normal saline solution and kept in tissue 
paper to remove the excess of blood. Brain tissue was mixed with 1 volume 
normal saline solution and homogenated in a tissue homogenizer, and 
supernatant was collected for analysis. Plasma samples and brain tissue 
homogenates were stored at −20°C until analysis. Drug concentrations in 
plasma samples and brain tissue homogenates were determined using LC/
MS technique. Internal standard (metoclopramide hydrochloride) 20 µl 
was added. Plasma and brain tissue homogenates samples were extracted. 
A mixture of diethyl ether and dichloromethane, 50:50 parts, was used 
as extracting solvent. A 2 ml of solvent was added and mixed and then 
centrifuged at 10,000 rpm (8°). Flash precipitation with chilled methanol 
took place. The supernatant was decanted thereafter. The remaining 
contents were evaporated at 35°C with the help of nitrogen evaporator. 
A mobile phase 200 µl was used to reconstitute the samples for LC/MS 
analysis. After extraction, study samples were run. These samples were 
run along with the calibration curve for quantitative analysis.
Pharmacokinetic studies
Pharmacokinetic parameters were derived from the study samples 
versus time plot. AUC, Cmax, and Tmax were estimated. AUC was statistically 
analyzed using software GraphPad Prism version 5.01. Brain targeting 
of drug was calculated by DTI as given by the following equation [26].
DTI =
(AUCbrain tissue / AUCplasma)i.n.
(AUCbrain tissue / AUCplasma)oral
RESULTS AND DISCUSSION
Estimation of drug content in oils, surfactants, and cosurfactants
The mixture of phosphate buffer pH 6.4 and methanol 1:9 v/v was 
selected to solubilize the drug from ME components, i.e. oil, surfactant, 
and cosurfactant. Various proportions of phosphate buffer pH 6.4 and 
methanol 9:1v/v–1:9 v/v were evaluated on the basis of solubility of 
a drug from ME components. The turbidity was observed where the 
proportion of phosphate buffer pH 6.4 was more. However, clarity 
improved as the proportion of methanol increased. Phosphate buffer 
pH6.4 and methanol in the ratio 1:9 v/v showed more clarity after 
miscibility of ME components in it, and hence, it was selected. This 
selected ratio of solvent was used to develop calibration curve of drug 
in it. λmax was found to be 244 nm (Linearity was observed from 2 to 
10 µg/ml, and R2 was 0.999).
Solubility studies
Oils of semi-synthetic nature were included in the present study. These 
were preferred intentionally to obtain reproducibility in results and 
stability of preparation. The order of solubility of frovatriptan succinate 
among the oils screened was capmul MCM followed by isopropyl 
myristate and oleic acid. 
The oil components constitute significant proportion in a ME formulation 
and the solubility in Capmul MCM was found and surfactant together is 
more than water alone. This value signifies drug carrying capacity and 
possible delivery to the brain. In practice, the drug gets solubilize in all 
components of a ME. Therefore, this affects drug loading, clarity, and 
overall appearance of formulation. Therefore, it was relevant to screen 
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surfactants and cosurfactants for solubility of the drug. Surfactants 
such as Cremophor EL showed maximum solubility of frovatriptan 
succinate followed by Tween 80. Cosurfactants such as propylene glycol 
and ethanol also showed good solubility of frovatriptan succinate in 
it. Solubility study was carried out at temperature 37±2°C. Excipients 
showing maximum solubility were used for the phase behavior study. 
As more drug loading was possible with this selection, Capmul MCM 
as oil phase, Cremophor EL as surfactant, and propylene glycol as 
cosurfactant were selected for further study. These components showed 
maximum solubility than other so selected for development of the 
ME formulation. It was thought that, apart from the role of surfactant 
and cosurfactant to reduce interfacial tension between oil and water 
components and to make them more miscible into each other, they are 
also serving as a solvent for frovatriptan succinate. Practically, it was 
observed that surfactants and cosurfactants have shown considerable 
solvent property for solubilization of frovatriptan succinate. Various 
oils, surfactants, and cosurfactants used for solubility studies are listed 
in Table 1. Oils, surfactants, and cosurfactants showing maximum 
solubility of drug were selected for further studies.
Construction of phase diagram and preparation of ME formulation
Pseudoternary phase diagrams consisting of oil (Capmul MCM), 
surfactant (Cremophor EL), cosurfactant (propylene glycol), and water 
are shown in Fig. 1, from which exact concentration ranges of different 
components of ME composition were obtained. The ME regions of Smix 
in various ratios 4:1, 3:1, and 2:1 were identified.
The shaded area in the diagrams shows the formation of the ME systems 
at room temperature. It was concluded that the highest ME zone was 
achieved for the MEs containing cremophor EL/propylene glycol at a 
ratio of 2:1. A maximum amount of water uptake was found for Capmul 
MCM and Cremophor EL/propylene glycol at 2:1 concentration [Table 2].
Preparation of drug-loaded ME
Frovatriptan succinate was partitioned into all components of the ME 
and finally formed a clear ME. Incorporation of frovatriptan succinate 
was found easy.
Characterization of ME formulations
Identification: Dilution test
No any phase separation was observed when diluted with an excess of 
water. However, when diluted with oil, immediately phase separation 
was observed. This indicated that continuous phase was water, and 
hence, ME was o/w type.
Identification: Filter paper test
A drop of ME was placed on a filter paper. Spreading and absorption of 
drop the surface indicated o/w type of ME. This test was carried out to 
confirm the above test.
pH of ME
The pH values of ME formulation are shown in Table 3. The pH values 
of all the formulations were found compatible with the nasal mucosa, 
Fig. 1: Pseudoternary phase diagram composed of Capmul MCM (oil), Cremophor EL (surfactant), propylene glycol (cosurfactant), and 
water at various S:Cos (Smix) ratios, (a) 4:1, (b) 3:1, (c) 2:1
c
ba
Table 1: Solubility of frovatriptan succinate in different oils, surfactants and cosurfactant
Oil Solubility (mg/ml) Surfactants Solubility (mg/ml) Co-surfactants Solubility (mg/ml) 
Capmul MCM 39.23±1.20 Cremophor EL 41.69±1.15 Propylene glycol 112.86±1.30
Isopropyl myristate 35.33±1.12 Tween 80 35.15±1.31 Ethanol 48.15±1.12
Oleic Acid 22.11±1.36 Cremophor RH-40 25.13±1.52 PEG 400 23.32±1.23
Maisine 35-1 13.24±1.28 Labrasol 15.04±1.08 Plurol olieque 15.63±1.12
Medium chain triglycerides 5.13±1.14 Labrafil M 2125 CS 12.34±1.21 - -
Data were expressed as mean±S.D., (n=3)
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which falls in nasal pH ranges from 4.5 to 6.5. Hence, it will not cause 
any nasal irritation after administration.
Viscosity
The significance of this study narrates its spreadability/drainage into 
the nasal cavity after application onto nasal mucosal sites. The viscosity 
of ME formulation was found low and it could be administered easily 
in the nasal cavity. Furthermore, low viscosity is suitable to fill ME in a 
container. Results are shown in Table 3. The rheological behavior of the 
ME was studied using small volume adaptor.
Refractive index
The refractive index is a measure of clarity. These MEs were characterized 
for their transparency to light. The values of the refractive index were 
nearer to the refractive index of water. This indicates good transparency 
of the prepared MEs. The refractive index of all MEs is shown in Table 3.
Particle size (globule size of dispersed phase) and zeta potential
Mean globule size of drug loaded all ME formulations are given in 
Table 3. Formulation F4 showed mean globule size of 457.5 nm which was 
maximum, whereas F5 has shown globule size of 142.0 nm which was least 
among all formulations. This is shown in Fig. 2. All the formulations, except 
F4, were showing globule size within the range of 20–200 nm which is well 
accepted for ME. Polydispersity index (PDI) indicates the uniformity of 
droplet size within the formulation. Higher the polydispersity index, lower 
the uniformity of the droplet size in the formulation. PDI is the measure 
of uniformity of particle size in the formulation and <1 is desirable [27]. 
All batches of MEs F1–F7 showed PDI in the range of 0.385–0.431. Thus, 
more uniformity in droplet size and more thermodynamic stability of 
formulations was obtained. Measurement of zeta potential was carried out 
to determine the stability of oil droplets in the ME system. Values of the 
zeta potential of all ME formulations are shown in Table 3. Practically, the 
values of the zeta potential of all formulations were found in the range of 
−17.7 to −7.8 mV. Aggregation of globules was observed due to the negative 
charge of the droplets. The values of zeta potential indicate that the system 
is not fully but relatively stable [28]. A negative value indicates that systems 
have good conductivity, so it also confirms that developed MEs were o/w 
type. Fig. 3 indicates the value of zeta potential of the optimized ME.
Drug content
The content of frovatriptan succinate in MEs as given in Table 3 was found 
to be in the range of 96.57±1.10 to 99.19±1.12%, which confirms almost 
complete solubilisation of drug in formulation resulting transparent 
solution. Drug-free ME (blank ME) diluted in a similar manner showed 
no significant peak at 244 nm indicating an absence of any interference.
In vitro drug diffusion study
To simulate physiological conditions in the nasal cavity, phosphate buffer 
6.4 and temperature 34°C were selected. Cumulative per cent  drug 
release through dialysis membrane of different ME formulations was 
found to be in the range of 65–85% at the end of 7 h. Formulation F5 has 
shown maximum drug release in 7 h (Fig. 4). Initially, for all formulations, 
drug release rate was faster due to release of drug present in the aqueous 
phase which is a continuous phase in ME and later on decreased may be 
due to drug release from oil droplets. Correlation coefficient, R2 equal 
to 0.9917 and 0.9909, showed first orders for F2 and F5 formulations, 
respectively. Formulation F6 has shown slow drug release and even 85% 
could not obtain in 7 h. This may due to the high viscosity of formulation 
as compared to others and probably due to thick gel-like structure 
formation due to the very high amount of surfactant used.
Ex vivo permeation study
As formulation F5 exhibited good in vitro drug release profile with 
favorable evaluation parameters, the formulation F5 was chosen 
to observe the permeation of drug through sheep nasal mucosa. 
The optimized ME (F5) was studied ex vivo for drug release from 
the sheep nasal mucosa for 7 h [29]. Permeation of the drug from 
optimized formulation, F5, was 82.32% and followed the Peppas 
model at the end of 7 h. Percentage drug release and average flux after 
7 h obtained 82.32% and 9.51 mcg/cm2/min, respectively. Thus, ME 
system composed of frovatriptan succinate is a promising approach for 
targeting drug in brain tissues.
Histopathological study
One of the requirements of formulation development is that formulation 
should not produce any nasal mucosal irritation [26]. The excipients 
were selected on the basis of “generally regarded as safe material.” 
This histopathology study helps to evaluate toxicity of ME using sheep 
nasal mucosa [30,31]. We can hypothesize the possible toxicity of said 
formulation to the human nasal mucosa. For better differentiation and 
confirmation, positive and negative controls were used to compare 
the effect of optimized ME (F5) on sheep nasal mucosa. The images of 
histopathology study are shown in Fig. 5.
From Fig. 5, the cellular structure of the nasal mucosa was retained 
after the treatment of the optimized ME formulation and phosphate 
buffer pH 6.4 and it is damaged with the positive control of IPA. It is 
seen under the microscope that original structure was not retained 
after treatment with IPA. Thus, there was no toxicity produced by the 
optimized ME. Hence, it can be concluded that the optimized ME was 
safe.
Mucoadhesive strength of the optimized ME formulation was carried 
out. The mucoadhesive strength of the tested formulation was found 
328.85±2.00 dyne/cm2.
Optimization using simplex lattice design
For the development of a ME system, various compositions of Smix were 
used. During trial batches, it was found that Smix compositions were 
Table 2: Simplex lattice design for the formulation of 
frovatriptan succinate microemulsion
batch Code Composition of independent variables (%)
Oil (X1) Surfactant (X2) Co-surfactant (X3)
F1 15.50 17.50 5
F2 20.00 15.00 5
F3 17.50 17.50 5
F4 20.00 15.00 5
F5 15.00 15.00 10
F6 15.00 20.00 5
F7 17.50 15.00 7.5
X1, X2 and X3 are apex points on triangle of simplex lattice design
Table 3: Evaluation parameter of microemulsion formulations F1-F7
Batch code pH Viscosity (cps) Refractive index Drug content (%) Particle size (nm) Zeta potential (mv)
F1 5.2±0.1 96±1.09 1.39±0.11 98.13±1.00 155.4 ‑10.6
F2 5.2±0.1 81±1.28 1.36±0.18 97.42±1.11 143.5 ‑17.7
F3 5.3±0.1 116±1.32 1.38±0.17 99.19±1.12 160.5 ‑13.4
F4 4.7±0.1 103±1.50 1.36±0.12 98.64±1.20 457.5 ‑9.28
F5 5.4±0.1 101±1.43 1.37±0.21 98.25±1.10 142.0 ‑7.8
F6 5.3±0.1 113±1.27 1.35±0.21 96.57±1.10 173.1 ‑10.4
F7 4.9±0.1 97±1.28 1.36±0.12 97.88±1.13 239.4 ‑8.35
Data were expressed as mean±S.D., (n=3)
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important parameters which may affect the drug release from the 
formulation. The factorial design was applied and carried out with the aim 
of finding the optimum concentration of oil, surfactant, and cosurfactant 
level to achieve a drug release above 85% from ME formulation. 
Simplex lattice design was helpful to evaluate the formulation of three-
component system. The total of mixture component was 100%. The 
percentage of drug release after 7 h was ranged from 65.63% to 86.33% 
in F1 to F7 ME formulations. The polynomial equations can be used to 
draw conclusions after considering the magnitude of the coefficient and 
the mathematical sign it carries, i.e., positive or negative.
The equation for drug release is as follows:
  
Ydrugrelease = 80.63 + 0.41X -12.35X - 2.89X + 0.76X X -
0.48X X
1 2 3 1 2
1 3 +1.27X X +1.01X X X2 3 1 2 3
To evaluate the percentage drug release equation (1), different 
models were selected. F value and p value imply that linear model was 
significant as shown in Table 4. X1 shows the agonistic effect to drug 
release. X2 and X3 show antagonistic effect. A common effect of X2X3 and 
X1X2X3 shows additive effect, while X1X3 shows negative effect. Hence, 
linear interaction increases drug release of the ME. Factor X2X3 has 
more significant effect on drug release through the dialysis membrane 
than other coefficients, thus necessary for drug release.
Response surface analysis
The linear models generated by regression analysis were further used 
to construct three-dimensional response plots, in which response 
parameter Y was represented by a curvature surface as a function of 
X. Fig. 6 shows the effect of three factors on percentage drug release at 
the end of 7 h and also shows a linear relationship between the three 
independent variables, i.e., X1, X2, and X3 on response Y (percentage drug 
release).
An optimization technique using the desirability approach was 
employed to develop a new formulation with the desired response. 
The new formulation was validated for percentage drug release. No 
significant difference was observed in experimental and predicted 
values of percentage drug release as shown in Table 5.
Animal study
Analytical procedure and sample preparation
Under chromatographic conditions, retention time was 2.08 min 
for frovatriptan succinate and 2.18 min for internal standard 
metoclopramide hydrochloride. A 0.1 % formic acid was added in the 
mobile phase to generate proton ions. ESI was performed using positive 
ion mode, and MRM fragmentation reaction was carried out for each 
drug. Quantification of protonated molecules of frovatriptan succinate 
at m/z 213.1 was occurred and m/z 227.2 for internal standard 
metoclopramide hydrochloride. Parent ion of frovatriptan succinate 
was determined at m/z 244.5, as the molecular weight of drug is 243.5 
(Fig. 7). Thus, it proves characteristic property of drug. Detection 
was performed using an API-4000 QTRAP instrument (Applied 
Biosciences ABsciex). A calibration curve was constructed in the range 
of 10–800 ng/ml. A mean correlation coefficient (R2) for the calibration 
curve was 0.9985. The accuracy for frovatriptan succinate was found to 
be in acceptable range (–15 to 15 %).
Fig. 2: Average globule size of the optimized microemulsion 
formulation
Fig. 3: Zeta potential of the optimized microemulsion 
formulation
Fig. 4: Drug release of nasal microemulsion formulations
Fig. 6: Response surface and contour plot for the effect of 
independent variable on drug release
Fig. 5: Histopathological evaluation of sheep nasal mucosa: 
(a) pH 6.4 negative control, (b) Isopropyl alcohol positive control, 
(c) optimized microemulsion formulation
cba
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Pharmacokinetics: Estimation of concentrations of drug in plasma
Pharmacokinetic parameters [32,33] were calculated from plasma 
concentration-time profiles and are shown in Fig. 8. Values of Cmax, Tmax, 
AUC0−6 (ng.h/ml), and ratio of (AUCbrain tissue/AUCplasma) % are shown in 
Table 6. The Cmax attained by frovatriptan in plasma by nasal ME was 2 
times greater than the oral solution. The AUC0−6 attained by nasal ME in 
plasma was 1.59 times greater than the oral solution. It was observed 
that Cmax was achieved higher in plasma by nasal ME compared to the 
oral aqueous solution at fixed time point.
Estimation of concentrations of drug in brain tissues
The Cmax attained by frovatriptan in the brain tissues by nasal ME was 
3.5 times greater than the oral solution. The AUC0−6 attained by nasal ME 
was 3.29 times greater than the oral solution. It was observed that Cmax 
was achieved higher in nasal ME compared to the oral aqueous solution 
at fixed time point.
Table 6 shows the concentration of frovatriptan succinate in the brain 
tissues following intranasal and oral administration. This is shown in 
Fig. 9. The ratio of (AUCbrain tissue/AUC plasma) % for nasal route and oral 
route was 42.11 and 20.39, respectively. Thus, brain–blood ratios 
of frovatriptan succinate were found to be higher for formulation 
administered nasally. This confirms direct nose to brain transport. 
The concentrations of frovatriptan succinate in the brain following 
intranasal administration of ME was found to be significantly higher 
at all sampling points compared to oral administration for 6 h. 
Therefore, it can be concluded that concentration of drug in brain 
tissue could be increase successfully by nasal route rather than the 
Table 4: Summary of ANOVA for dependent variables from simplex lattice design
Response Sum of squares Df Mean square F value p value
Percentage drug release 285.65 5 57.13 254.53 0.0475 significant
p< 0.05
Table 5: Validation of optimized batch F5
S. No. Parameter Experimental value Predicted value Percentage error
1 Percentage drug release 86.33% 84.88% +1.67
Percent error not significant; tested for optimized formulation
Table 6: Pharmacokinetic parameters of frovatriptan succinate-loaded microemulsion for oral and nasal route
Pharmacokinetic parameters Route of administration Plasma Brain tissues
Tmax (h) Nasal 2±0.00 2±0.00
Oral 2±0.00 2±0.00
Cmax (ng/ml) Nasal 331±3.72 181±1.51
Oral 161±4.22 52±1.08
AUC 0-6 (ng.h/ml) Nasal 926.1±4.71 390.0±2.08
Oral 581.5±2.42 118.6±2.70
AUC brain tissue/AUC plasma (%) i) Nasal 42.11
ii) Oral 20.39
DTI --- 2.06
Data were expressed as mean±S.D., (n=3), DTI: Drug targeting index
Fig. 7: MS tune of frovatriptan succinate
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oral route [15]. Amount of frovatriptan succinate in brain tissue after 
nasal administration is attributed to two pathways through systemic 
pathway and olfactory pathway; however, the latter is major [34]. 
Jaiswal et al. described mechanism of brain targeted intranasal delivery 
via olfactory epithelium [35].
Estimation of drug targeting
The DTI for brain tissue was calculated [33]. DTI represents a 
time average partitioning ratio. DTI 2.06 was found satisfactory. It 
indicates that nasal route is an alternative pathway for frovatriptan 
succinate acting on brain tissues through the olfactory pathways. 
From pharmacokinetic studies, it can be concluded that nasal route 
provides a passage for frovatriptan succinate to reach into brain 
tissues. The component of optimized ME was suitable for frovatriptan 
succinate for permeation across the nasal mucosa through olfactory 
pathways.
Stability study was carried out in the humidity chamber (Oswal 
Scientific) where the temperature was set at 40±2°C/75±5% relative 
humidity for 3 months. At every 2 weeks, samples were withdrawn 
and analyzed for physicochemical parameters. At the end of 3rd month, 
the comparative study was tabulated and any change in macroscopic 
appearance such as transparency, homogeneity, drug precipitation, 
turbidity, pH, refractive index, drug content %, and drug released was 
evaluated. There was no significant difference between the initial and 
respective values during and at the end of the study.
CONCLUSION
To conclude, the ME of frovatriptan succinate was successfully prepared 
by the ME of frovatriptan succinate was successfully prepared by water 
titration method and demonstrated in Swiss albino rats to deliver 
frovatriptan succinate in effectively to the brain following intranasal 
administration. This study demonstrated the effectiveness and 
feasibility of intranasal delivery of frovatriptan succinate through ME. 
Further clinical data are needed to produce benefit-to-risk ratio for 
suitability in clinical study and practice.
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